基本信息
浏览量:5
职业迁徙
个人简介
Research interests
Study of the asthma susceptibility gene A Disintegrin and Metalloprotease 33 (ADAM33) in early life and adult asthma and other chronic lung diseases.
Development of novel Anti-ADAM33 agents as potential disease modifying asthma therapy.
Multiomic study of the influence of the maternal environment (e.g. allergic asthma, obesity) during pregnancy on ADAM33 and other mediators and the early origin of lung disease in the Maternal Environment in Pregnancy (MEP) cohort.
Study of difficult-to-treat/severe asthma in the Wessex AsThma CoHort of Difficult Asthma (WATCH), a pragmatic real-life longitudinal study of difficult asthma in the clinic.
研究兴趣
论文共 123 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ERJ OPEN RESEARCHno. 6 (2023): 00590-2023
The journal of allergy and clinical immunology. In practiceno. 9 (2023): 2812-2821.e4
Jennifer Naftel, Heena Mistry, Frances Ann Mitchell, Jane Belson, Mohammed Aref Kyyaly,Clair Barber,Hans Michael Haitchi,Paddy Dennison, Ratko Djukanovic, Gregory Seumois, Pandurangan Vijayanand, Syed Hasan Arshad,
Journal of Asthma and Allergy (2023): 1333-1345
Cristina Parenti,Alice M. Murphy,Nikita Lad,Philip G. McTernan, Carl P. Nelson,Graham R. Sharpe,Claire Barber, Rana Abadalkareem, Adnan Azim,Ramesh J. Kurukulaaratchy,Hans M. Haitchi,Neil C. Williams
Endocrine Abstracts (2022)
H Rupani, D Edwards, J Richards,R Chaudhuri,S Smith,DJ Jackson, A Hearn, M Edwards, S Johnston, H Moyses, RJ Kurukulaaratchy,HM Haitchi,
‘Infinity War’ – Ongoing clinical challenges in COVID-19 (2022): A174-A174
引用0浏览0引用
0
0
CLINICAL AND EXPERIMENTAL ALLERGYno. 6 (2022): 792-796
‘Finding Neverland’ – T2 inflammation and its absence (2022): A80-A80
05.01 - Airway pharmacology and treatment (2022): A89-A89
C. Parenti, A. M. Murphy,N. Lad,P. G. McTernan, C. P. Nelson,G. R. Sharpe,C. Barber, R. Abadalkareem,A. Azim,R. J. Kurukulaaratchy,H. M. Haitchi,N. C. Williams
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn